Today's ASCO-2016 Oral Presentation on MSS-CRC PDL1-MEK Immunotherapy Success

Please feel free to read, share your thoughts, your stories and connect with others!
User avatar
DK37
Posts: 510
Joined: Tue Sep 17, 2013 8:31 am
Location: San Diego

Today's ASCO-2016 Oral Presentation on MSS-CRC PDL1-MEK Immunotherapy Success

Postby DK37 » Mon Jun 06, 2016 12:21 am

Here's my analysis of the big MEK + PDL1 immunotherapy trial results presented at ASCO-2016 today for MSS CRC! The data looked really good for a "1st big step forward" in MSS CRC immunotherapy - and importantly it shows that the concept of immunotherapy CAN work for MSS CRC - you just need a PD1 co-therapy. That was a strong scientific hypothesis previously, today it is a clinical data fact.

MEK inhibitors (today's co-therapy was a "MEK inhibitor") are just one example - as you know they are testing other co-therapies in clinical trials... So I consider today the STARTING POINT of MSS CRC immunotherapy success – not the grand finale!

Another point to make: other companies have MEK & PD1 inhibitors - so in addition to the announced randomized Phase 3 trial - I anticipate there will probably be new Phase 1 trials starting up for MSS CRC with other companies' MEK/PD1 inhibitors which will guarantee you get the drug.

A big scientific step forward for MSS-CRC today-

https://adventuresinlivingterminallyopt ... al-cancer/

Cheers!
-DK
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
7/12 FOLFOX/FOLFIRI
2/13 NED!
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
3/15 Cetuximab
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)
MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/
2016 Colondar 2.0 Model
DK37 Science Posts List

Stanfordmom
Posts: 613
Joined: Wed May 14, 2014 1:32 am

Re: Today's ASCO-2016 Oral Presentation on MSS-CRC PDL1-MEK Immunotherapy Success

Postby Stanfordmom » Mon Jun 06, 2016 1:15 am

Tom,

This is very exciting. thank you for posting!
Sha
DX 4/2/2014 at 44, stage 4, mets liver and ovaries
Mom to 2 boys
Three surgeries, HAI pump and lots of chemo
fighting!

User avatar
juliej
Posts: 2859
Joined: Thu Aug 05, 2010 12:59 pm

Re: Today's ASCO-2016 Oral Presentation on MSS-CRC PDL1-MEK Immunotherapy Success

Postby juliej » Mon Jun 06, 2016 6:06 pm

Thanks for the update, Tom. Looks like they demonstrated the mechanism and the benefit so things are definitely looking up for MSS-CRC! The efficacy chart (waterfall plot) was impressive. And what a relief to see the response is durable in some patients. I'm anxious to see the results in KRAS-wildtype in the phase 3 trial though. Worried that BRAF mutation/MEK inhibition are connected.

Your question ("Does MEK inhibition with cobimetinib convert some MSS tumors into a “MSI-high-like” status?") is pertinent considering PD-L1 expression didn't correlate with response.

Like you, I suspect that now we'll start seeing other company's MEK/PDL1 combos, building on the success of this one. One crack in the wall. All we need is to make that crack bigger and the whole damn wall comes down! :D
Stage IV, liver/lung mets 8/4/2010
Xelox+Avastin 8/18/10 to 10/21/11
LAR, liver resec, HAI pump 11/11
Double lung surgery + ileo reversal 2/12
Adjuvant Xeloda 3-9/12
VATS rt. lung 12/21/12 - benign granuloma!
NED 3/17/12 to 7/13/2018, CEA<1

User avatar
DK37
Posts: 510
Joined: Tue Sep 17, 2013 8:31 am
Location: San Diego

Re: Today's ASCO-2016 Oral Presentation on MSS-CRC PDL1-MEK Immunotherapy Success

Postby DK37 » Wed Jun 08, 2016 9:06 am

juliej wrote:Like you, I suspect that now we'll start seeing other company's MEK/PDL1 combos, building on the success of this one. One crack in the wall. All we need is to make that crack bigger and the whole damn wall comes down! :D


:D

-DK
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
7/12 FOLFOX/FOLFIRI
2/13 NED!
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
3/15 Cetuximab
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)
MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/
2016 Colondar 2.0 Model
DK37 Science Posts List

boswind
Posts: 40
Joined: Fri Apr 11, 2014 12:04 pm

Re: Today's ASCO-2016 Oral Presentation on MSS-CRC PDL1-MEK Immunotherapy Success

Postby boswind » Wed Jun 08, 2016 7:55 pm

Here is the link to the relevant article presented at ASCO-2016:

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)
http://meetinglibrary.asco.org/print/2390996
01.24.2014 Male, DX @54 Rectosigmoid Cancer, MRI: T3N0M0
03.19.2014 Completed 5-week Radia+Xeloda
05.07.2014 Had surgery
02.25.2015 CT showed liver and L4 Spine involvement.
03.2015 - 08.2015, folfox + Avastin
08.2015 - 07.2017, 5FU + leucovorin + Avastin for Maintenance
07.2017 - 01.2018, Folfuri + Avastin
01.25.2018 - present, Centuximab + Irinotecan
70 rounds of chemos received (as of 03.2018)
Current CEA: 5.7
MSS, KRAS wild type, BRAF wild type

User avatar
Nik Colon
Posts: 5210
Joined: Thu Jan 08, 2015 3:35 pm
Location: MN

Re: Today's ASCO-2016 Oral Presentation on MSS-CRC PDL1-MEK Immunotherapy Success

Postby Nik Colon » Wed Jun 08, 2016 8:45 pm

Thanks DK :)
KRAS-mut G12V,MSS
Stage IVa Sig CC 2 lvr mets 1/12 Ln
(3, =<3 lng spots at dx til 5/16)
=T3N1aM1a 4cmX4mm (lng not included)
dx 12/2014 at age 39
CEA 1/15-4.9, 12/16-4.9 again
neoadj FOLFOX 1/15-3/15 (4tx, 3w/1wo oxi)
Col/Lvr surg 4/23/15 NED
adj FOLFIRI start 6/15-9/15 (8tx, 5w/3wo iri)
1 sml lvr spot/cyst
12/6/16 multi lung spots/mets?
No longer NED :(
My tx ongoing-start 1/20/15
Adding your SIGNATURE, etc

User avatar
DK37
Posts: 510
Joined: Tue Sep 17, 2013 8:31 am
Location: San Diego

Re: Today's ASCO-2016 Oral Presentation on MSS-CRC PDL1-MEK Immunotherapy Success

Postby DK37 » Thu Jun 09, 2016 6:19 am

boswind wrote:Here is the link to the relevant article presented at ASCO-2016:

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)
http://meetinglibrary.asco.org/print/2390996



Thanks for the official link Boswind!

-DK
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
7/12 FOLFOX/FOLFIRI
2/13 NED!
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
3/15 Cetuximab
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)
MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/
2016 Colondar 2.0 Model
DK37 Science Posts List

EverySunriseCounts
Posts: 19
Joined: Sun Jan 17, 2016 1:25 pm

Re: Today's ASCO-2016 Oral Presentation on MSS-CRC PDL1-MEK Immunotherapy Success

Postby EverySunriseCounts » Fri Jun 10, 2016 2:00 pm

HI @DK37 and all:

So we're moving ahead with immunotherapy, and the doctors are recommending that we do the tests from Foundation Medicine.

There was an article about them in GenomeWeb (paywalled) so I'm repeating it here. The important thing is that EVEN IF YOU ARE MSS, you may have a high "tumor mutation burden" (TMB) that makes some of the existing immunotherapy treatments effective for you. If you're considering immunotherapy and want to review your options, please read this. Sorry for the wall-o-text!! Bolded the important bits.


CHICAGO (GenomeWeb) – Studies presented at this week's annual meeting of the American Society of Clinical Oncology contained new evidence supporting the use of Foundation Medicine's targeted sequencing test FoundationOne to extrapolate a cancer patient's genome-wide tumor mutation burden in order to potentially guide the use of immunotherapeutic drugs.

Foundation Medicine has said it plans to develop a CLIA-certified version of this tumor mutation burden analysis, which it will provide to physicians as part of FoundationOne and FoundationOne Heme reports by the third quarter of 2016.
In the meantime, the company and its collaborators are building evidence for the clinical utility of this added analysis, with numerous studies presented at ASCO this week, most supporting the plausibility of using FoundationOne to infer genome-wide mutation loads, but some also linking the test to patient outcomes.

During a clinical science symposium that focused on biomarkers for response to anti-PD-1 drugs, researchers from Memorial Sloan-Kettering Cancer Center, led by Jonathan Rosenberg, presented a retrospective study of participants in the Imvigor210 trial of Roche's Tecentriq (atezolizumab) in metastatic urothelial cancer.

The investigators tested a number of assays — Ventana's SP142 PD-L1 immunohistochemistry assay, which was approved last month as a complementary diagnostic to atezolizumab; RNA sequencing to assess gene expression; and Foundation Medicine's 315-gene FoundationOne test to extrapolate genome-wide mutational burden.

Overall, Rosenberg and his colleagues concluded that PD-L1 expression, tumor mutation burden, and TCGA subtype can act as independent predictors of atezolizumab sensitivity.
In the same symposium, another group of researchers from Vanderbilt University, Foundation Medicine, Adaptive Biotechnologies, and the University of Texas, Southwestern shared data from a study in which they used FoundationOne as a proxy for overall mutational load in melanoma samples.
The results demonstrated a strong correlation between mutational burden, as measured by the FoundationOne panel, and the exome-wide frequency of mutations identified in 300 melanoma samples from TCGA.
Beyond these oral presentations, the conference also saw a handful of poster presentations by Foundation Medicine and academic colleagues.In one, Foundation Medicine bioinformatics director Garrett Frampton and co-authors highlighted results from a study in which they used FoundationOne sequencing data from over 60,000 clinical cases across more then 400 cancer types to determine patterns of tumor mutation burden (TMB) across a wide spectrum of cancers.

The team identified numerous cancer types — for example certain types of stomach and uterine cancers — in which they saw many high-TMB cases, but for which cancer immunotherapy is not currently approved. This finding, the group wrote, supports other similar results and suggests a need for broader pan-cancer access to clinical trials for these therapies.

The group also reported on their validation of the accuracy of the FoundationOne-based TMB calculation by comparing it to whole-exome tumor mutation levels. For this, they compared TCGA whole-exome variant calls for 7,000 subjects to variant calls representing only the portion of the genome covered by FoundationOne.

This analysis, as well as a small second validation study in 16 matched samples that received clinical FoundationOne testing and whole-exome sequencing, both showed a high correlation between the FoundationOne TMB assessment and exome-wide TMB.
In a subset of about 35,000 samples, the researchers also compared FoundationOne-based TMB to microsatellite instability (MSI) — another known predictor of immunotherapy response. While most samples with high MSI also showed a high TMB, there were many microsatellite-stable samples that were nonetheless highly mutated. Overall, the authors wrote, only 15 percent of the high TMB cases also had high MSI, implying that TMB could help identify additional patients who might benefit from immunotherapy and would be missed by MSI testing alone.
In another poster, researchers led by Thomas George from the University of Florida shared additional data from a study comparing tumor mutation burden as assessed by FoundationOne with microsatellite instability status in more than 2,000 subjects with colorectal cancer.
While all of the patients in this analysis that had high microsatellite instability also had high TMB based on FoundationOne, there were also more than 400 subjects who had microsatellite stable cancers, but a high TMB.
Though the study did not look at immunotherapy responses in this MS-stable, TMB-high group, the authors were able to show that this group and the MSI-high patients had gene signatures in common. According to George and his co-authors, the results suggest FoundationOne-based TMB might be able to pick out more immunotherapy responders than MSI status alone, although that would have to be borne out in therapeutic outcomes data.

In yet another study, this one in lung cancer patients, researchers led by David Spigel of the Sarah Cannon Research Institute evaluated FoundationOne-based TMB status, PD-L1 expression, and MSI status.
Their results showed that while only a fraction of lung cancers analyzed tested positive for high MSI or for PD-L1 expression, a significant number had high TMB, implying that if TMB truly is a marker of response to immunotherapy in these patients, it appears to be a more sensitive tool to identify possibly responsive patients.

According to Foundation Medicine Chief Medical Officer Vincent Miller, who spoke with GenomeWeb before the ASCO conference, the company also plans to incorporate a microsatellite stability status readout into its test reports.
"We have completed a robust validation with PCR and IHC, which shows near perfect concordance between our calls on MSI status and those by the 'conventional modalities'," Miller said.

Physicians more familiar with MSI as a marker of immunotherapy response than TMB may be better served by having this particular marker pulled out on its own, Miler explained. At the same time, data presented at the conference highlighted that many patients that do not have high MSI still can have high TMB, suggesting they should be reported independently.

In addition to the two studies presented at the conference, in melanoma and urothelial cancer, a few other pieces of early data at the meeting also connected FoundationOne-based TMB status with immunotherapy response.
In one, researchers led by Alessandro Santin of Yale University used FoundationOne to assess targetable mutations, TMB, and MSI status in samples from patients with endometrial adenocarcinoma.

The results demonstrated that TMB might identify additional patients likely to respond to immunotherapy that MSI testing does not. In addition, the Yale group's poster mentioned briefly that both patients with high MSI and patients with stable microsatellites but high TMB ,including two cases initially excluded by standard testing, who started on immune checkpoint inhibitors have shown early clinical benefit.

As excitement around the new class of cancer immunotherapies continues to grow, evidence is also accumulating that there will be a need for multiple biomarkers or approaches for predicting immunotherapy response and that no single measure — whether PD-L1 expression, mutation burden, or T-cell status — should be used on its own to exclude patients from immunotherapy.

This was a point of agreement amongst speakers at ASCO, and was also recently highlighted in Science by researchers from the Netherlands Cancer Institute and the University of California, Los Angeles, who proposed a multi-pronged approach they call a "cancer immunogram" — which includes mutational burden, PD-L1, and a number of other immunological factors — for assessing an individual cancer patient's likelihood of responding to cancer immunotherapies.

"While there are likely multiple determinants of response to these classes of agents, there is emerging data that TMB is one of the most powerful we have, at least as a single measure or metric," Miller told GenomeWeb.
"What we've seen and shown to date … is that we can, as a natural byproduct of the [FoundationOne] test — not really changing anything about the assay, get an estimate of tumor mutational burden which correlates well with overall mutational burden as assessed by whole-exome sequencing," Miller said.
The utility of a FoundationOne-based TMB test will likely vary from cancer type to cancer type, he added. For example, in melanoma, where responsiveness to checkpoint inhibitors is high, it would be improper to use TMB to exclude patients from therapy, but it might help identify patients who are likely to have a more durable versus a more transient response, guiding the latter toward combination regimens.

The company is planning to make this type of analysis clinically available this year. In the meantime, Miller said that physicians who have appropriately consented their patients can order a TMB analysis as a research use-only service.
Partner:
-Diagnosed with Stage IV CRC 09/14, liver,lymph mets
-Started Folfox
- Emergency surgery 10/14, removed colon tumor, temp ileostomy
- New abdominal tumor 05/15 changed to Folfiri
- Added Avastin 09/15
- Stable scan (liver mets still present) 11/15
- Stable scan 02/16; chemo halted 03/25
-Ostomy reversal 05/16

User avatar
DK37
Posts: 510
Joined: Tue Sep 17, 2013 8:31 am
Location: San Diego

Re: Today's ASCO-2016 Oral Presentation on MSS-CRC PDL1-MEK Immunotherapy Success

Postby DK37 » Fri Jun 10, 2016 5:06 pm

EverySunriseCounts wrote:HI @DK37 and all:

So we're moving ahead with immunotherapy, and the doctors are recommending that we do the tests from Foundation Medicine.

There was an article about them in GenomeWeb (paywalled) so I'm repeating it here. The important thing is that EVEN IF YOU ARE MSS, you may have a high "tumor mutation burden" (TMB) that makes some of the existing immunotherapy treatments effective for you. If you're considering immunotherapy and want to review your options, please read this. Sorry for the wall-o-text!! Bolded the important bits.


Thank you for posting this interesting article EverySunriseCounts!

-DK
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
7/12 FOLFOX/FOLFIRI
2/13 NED!
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
3/15 Cetuximab
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)
MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/
2016 Colondar 2.0 Model
DK37 Science Posts List

saffa
Posts: 19
Joined: Sun Nov 15, 2015 7:20 am
Facebook Username: Alexandra bergs

Re: Today's ASCO-2016 Oral Presentation on MSS-CRC PDL1-MEK Immunotherapy Success

Postby saffa » Fri Jun 10, 2016 5:20 pm

Second that - this is a very interesting read! Thank you :)
25 yo Female diagnosed 10/10/15 Stage IV (sigmoid primary and liver mets inoperable)
KRAS-mut (G12V) Tp53-mut MSS
Folfox 10/15-04/16
HAI/LAR @ MSK 02/16
CEA rising
Lung nodules confirmed 05/16
Switch to Folfiri/FUDR/Mitomycin 05/16
Looking for clinical trials
CEA dropped from 842 (05/02/16) to 257 (06/29/16) - scan confirms liver and lung shrinkage

saffa
Posts: 19
Joined: Sun Nov 15, 2015 7:20 am
Facebook Username: Alexandra bergs

Re: Today's ASCO-2016 Oral Presentation on MSS-CRC PDL1-MEK Immunotherapy Success

Postby saffa » Fri Jun 10, 2016 9:24 pm

Article specifically re colon cancer and TMB testing on FoundationOne website:

http://www.foundationmedicine.com/2016/ ... o-therapy/
25 yo Female diagnosed 10/10/15 Stage IV (sigmoid primary and liver mets inoperable)
KRAS-mut (G12V) Tp53-mut MSS
Folfox 10/15-04/16
HAI/LAR @ MSK 02/16
CEA rising
Lung nodules confirmed 05/16
Switch to Folfiri/FUDR/Mitomycin 05/16
Looking for clinical trials
CEA dropped from 842 (05/02/16) to 257 (06/29/16) - scan confirms liver and lung shrinkage


Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”



Who is online

Users browsing this forum: Brearmstrong, NHMike, Punky44 and 50 guests